Clinical trial · Observational
SBRT Treatment for Lung Metastasis From Soft Tissue Sarcoma
Phase II Study to Evaluate Feasibility and Safety of Stereotactic Body Radiation Radiotherapy (SBRT) for Lung Metastases From Soft Tissue Sarcoma
NCT02561559CI-TRIAL-00058249unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In this study the investigators treat PM oligometastatic patients with SBRT. Our objective is to evaluate rate of local control of treated lesions in patients treated with Intensity Modulated Radiation Therapy (IMRT) using Volumetric Modulated Arc Therapy (VMAT) for lung metastases from STS.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastasis From Malignant Tumor of Soft Tissues | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Lung metastasis from soft-tissue sarcoma | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Lung metastasis from soft-tissue sarcoma
- description
- Lung metastases from soft-tissue sarcoma
- interventionNames
- Radiation: Lung metastasis from soft-tissue sarcoma
Primary outcomes (1)
- measure
- Local control of treated lesions
- timeFrame
- 12 months
- description
- Evaluation of proportion of patients free from progression from starting radiotherapy
Secondary outcomes (2)
- measure
- Overall survival of treated patients
- timeFrame
- 4 years
- description
- Evaluation of proportion of patients alive
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 85 Years
Show eligibility criteria text
Inclusion Criteria: * Age 18 anni -85 years * PS according to ECOG 0-2 * Histopathologically confirmation of soft tissue sarcoma * Metastatic lung lesion less than 4 * Controlled primary tumor and other metastatic lesions * Metastatic lesion less than 5 such as the definition of oligometastatic patients * Written informed consent * Contraindication to surgical resection * Estimated survival ≥ 3 months * Absence of progressive disease longer than 6 months * No chemotherapy was given for at least 3 months after SBRT * Maximum diameter ≤ 5 cm Exclusion Criteria: * Prior thorax radiation therapy * Age \> 85 years * PS according to ECOG \>2 * Pregnant women * Maximum diameter ≥ 5.1 cm * Total volume of lung lesion greater than 1/3 of the whole pulmonary parenchima
References
Publications (1)
- BACKGROUNDNavarria P, Ascolese AM, Cozzi L, Tomatis S, D'Agostino GR, De Rose F, De Sanctis R, Marrari A, Santoro A, Fogliata A, Cariboni U, Alloisio M, Quagliuolo V, Scorsetti M. Stereotactic body radiation therapy for lung metastases from soft tissue sarcoma. Eur J Cancer. 2015 Mar;51(5):668-74. doi: 10.1016/j.ejca.2015.01.061. Epub 2015 Feb 13. PMID 25686482